This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ogiso, Y. Articles by Tsuruo, T. Search for Related Content PubMed PubMed Citation Articles by Ogiso, Y. Articles by Tsuruo, T.

Proteasome Inhibition Circumvents Solid Tumor Resistance to Topoisomerase II-directed Drugs¹

Yasunari Ogiso, Akihiro Tomida, Shuhong Lei, Satoshi ura and Takashi Tsuruo²

Institute of Molecular and Cellular Biosciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan [Y. O., A. T., S. L., T. T.]; Kitasato Institute, Minato-ku, Tokyo 108-8642, Japan [S. .]; and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Toshima-ku, Tokyo 170-8455, Japan [T. T.]

Physiological cell conditions, such as glucose deprivation and hypoxia, play a role in developing drug resistance in solid tumors. These tumor-specific conditions cause decreased expression of DNA topoisomerase II (topo II), rendering cells resistant to topo II-targeted drugs, such as etoposide and doxorubicin. We show here that inhibition of proteasome attenuated drug resistance by inhibiting topo II depletion induced by glucose starvation and hypoxia. topo II restoration was seen only at the protein levels, indicating that the topo II protein depletion occurred through a proteasome-mediated degradation mechanism. The stress-induced etoposide resistance was effectively prevented in vitro by the proteasome inhibitor lactacystin in both intrinsically resistant and sensitive tumor cells (colon cancer HT-29 and ovarian cancer A2780 cells, respectively). Furthermore, lactacystin effectively enhanced the antitumor activity of etoposide in the refractory HT-29 xenograft. These results indicate that lactacystin could serve as a new therapeutic agent to circumvent resistance to topo II-targeted chemotherapy in solid tumors.

This article has been cited by other articles:

				P. M Voorhees, E C. Dees, B. O'Neil, and R. Z Orlowski The Proteasome as a Target for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 153 - 170. [Abstract] [Full Text] [PDF]

				L. J. Frederiksen, R. Sullivan, L. R. Maxwell, S. K. Macdonald-Goodfellow, M. A. Adams, B. M. Bennett, D. R. Siemens, and C. H. Graham Chemosensitization of Cancer In vitro and In vivo by Nitric Oxide Signaling Clin. Cancer Res., April 1, 2007; 13(7): 2199 - 2206. [Abstract] [Full Text] [PDF]

				R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215. [Abstract] [Full Text] [PDF]

				M. Creighton-Gutteridge, J. H. Cardellina II, A. G. Stephen, A. Rapisarda, B. Uranchimeg, K. Hite, W. A. Denny, R. H. Shoemaker, and G. Melillo Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1{alpha} Protein Accumulation by NSC 644221 Clin. Cancer Res., February 1, 2007; 13(3): 1010 - 1018. [Abstract] [Full Text] [PDF]

				S. Ceruti, A. Mazzola, and M. P. Abbracchio Proteasome Inhibitors Potentiate Etoposide-Induced Cell Death in Human Astrocytoma Cells Bearing a Mutated p53 Isoform J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1424 - 1434. [Abstract] [Full Text] [PDF]

				M. H. Shah, D. Young, H. L. Kindler, I. Webb, B. Kleiber, J. Wright, and M. Grever Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6111 - 6118. [Abstract] [Full Text] [PDF]

				H.-R. Park, A. Tomida, S. Sato, Y. Tsukumo, J. Yun, T. Yamori, Y. Hayakawa, T. Tsuruo, and K. Shin-ya Effect on Tumor Cells of Blocking Survival Response to Glucose Deprivation J Natl Cancer Inst, September 1, 2004; 96(17): 1300 - 1310. [Abstract] [Full Text] [PDF]

				C. N. Papandreou and C. J. Logothetis Bortezomib as a Potential Treatment for Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5036 - 5043. [Abstract] [Full Text] [PDF]

				J. Yun, A. Tomida, T. Andoh, and T. Tsuruo Interaction between Glucose-regulated Destruction Domain of DNA Topoisomerase II{alpha} and MPN Domain of Jab1/CSN5 J. Biol. Chem., July 23, 2004; 279(30): 31296 - 31303. [Abstract] [Full Text] [PDF]

				G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]

				H.-F. Zhang, A. Tomida, R. Koshimizu, Y. Ogiso, S. Lei, and T. Tsuruo Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex Cancer Res., February 1, 2004; 64(3): 1114 - 1121. [Abstract] [Full Text] [PDF]

				P. M. Voorhees, E. C. Dees, B. O'Neil, and R. Z. Orlowski The Proteasome as a Target for Cancer Therapy Clin. Cancer Res., December 15, 2003; 9(17): 6316 - 6325. [Abstract] [Full Text] [PDF]

				Y. Ogiso, A. Tomida, and T. Tsuruo Nuclear Localization of Proteasomes Participates in Stress-inducible Resistance of Solid Tumor Cells to Topoisomerase II-directed Drugs Cancer Res., September 1, 2002; 62(17): 5008 - 5012. [Abstract] [Full Text] [PDF]

				N. E. Matthews, M. A. Adams, L. R. Maxwell, T. E. Gofton, and C. H. Graham Nitric Oxide-Mediated Regulation of Chemosensitivity in Cancer Cells J Natl Cancer Inst, December 19, 2001; 93(24): 1879 - 1885. [Abstract] [Full Text] [PDF]

				L. M. Brandes, Z. P. Lin, S. R. Patierno, and K. A. Kennedy Reversal of Physiological Stress-Induced Resistance to Topoisomerase II Inhibitors Using an Inducible Phosphorylation Site-Deficient Mutant of Ikappa Balpha Mol. Pharmacol., September 1, 2001; 60(3): 559 - 567. [Abstract] [Full Text] [PDF]

				J. A. Vrana and S. Grant Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade Blood, April 1, 2001; 97(7): 2105 - 2114. [Abstract] [Full Text] [PDF]